Theratechnologies To Present At Upcoming Investor Conferences On October 29 And November 10, 2020

Montreal, Canada – October 22, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that management will be presenting at the following upcoming virtual investor conferences. Riley Securities Liver Disease Therapeutics Day Thursday, October 29, 2020 Panel discussion with Dr. Christian …Lire la suite

Theratechnologies Appoints Two New Board Members

Montreal, Canada – October 16, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Mr. Andrew Molson and Mr. Alain Trudeau as new independent members to its Board of Directors. “Both Andrew and Alain bring tremendous value to …Lire la suite

Theratechnologies Confirms Issuance Of U.S. Patent Covering The Use Of Tesamorelin In The Treatment Of Individuals Suffering From NAFLD/NASH

Montreal, Canada – October 13, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,799,562, which is directed to the treatment of Nonalcoholic Steatohepatitis (NASH) …Lire la suite

Theratechnologies To Present At The H.C. Wainwright 4th Annual NASH Investor Conference On October 5

Montreal, Canada – September 30, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, will present at the H.C. Wainwright 4th Annual NASH Investor Conference on Monday, October 5, 2020 …Lire la suite

Theratechnologies To Develop Tesamorelin For The Treatment Of Nash In The General Population

Phase 3 protocol to be filed in Q4 2020; trial expected to begin early 2021  Clinical study to include HIV cohort Montreal, Canada – September 10, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to …Lire la suite

Theratechnologies Announces Launch Of Trogarzo® In Germany

First commercial launch in Europe Montreal, Canada – September 10, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that Trogarzo® will be commercially available in Germany as of tomorrow through its subsidiary, Theratechnologies Europe Limited.